NUVL Nuvalent, Inc.

BEARISH Impact: 7/10 Insider Cluster (3 insiders)
Horizon days Filed Mar 25, 2026 Processed 2mo ago
Insider cluster: 2 insiders, $1.7M total
Latest settled — T+20d ⚠ clustered
NUVL ▲ +10.22% at T+20d
SHORT call ✗ call lost -10.22% · α vs SPY -2.36% · entry $98.00 → $108.02
Next anchor: T+60d in 8d
Currently $123.25 · -25.77% from $98.00 entry (call sign-flipped)
Entry anchored
Mar 24, 03:59 PM ET
via Databento tick
T+1d
+0.06%
call -0.06% · α -1.83%
$98.06
settled 3mo ago
T+5d
+7.80%
call -7.80% · α -8.04%
$105.64
settled 2mo ago
T+20d
+10.22%
call -10.22% · α -2.36%
$108.02
settled 7w ago
T+60d
call — · α —
in 8d

Price Chart

Loading chart...

Executive Summary

Three C-suite executives at Nuvalent sold a combined $1.71M in shares over a 7-day period, including CFO Alexandra Balcom who sold $1.37M — the largest individual transaction. These were open-market sales, not tax-related or non-cash events, and represent a coordinated exit by senior insiders.

Key Financial Metrics

Direction
selling
Total Value
$1.7M
Insiders
3

Actionable Insight

Coordinated selling by multiple C-suite executives, especially the CFO, signals potential lack of confidence in near-term prospects. Traders should monitor upcoming earnings, pipeline updates, or clinical trial data for downward revisions or delays that may not yet be public.

Key Facts

  • CFO Alexandra Balcom sold 13,700 shares for $1.37M at $100.16 per share on March 25, 2026
  • Chief Development Officer Darlene Noci sold 2,532 shares for $246,693 at $97.43 on March 30, 2026
  • Chief Legal Officer Deborah Miller sold 940 shares for $91,650 at $97.50 on March 26, 2026
  • Total open-market sales: $1.71M across three C-suite executives in seven days
  • Non-cash derivative exercises also occurred but are not economically significant

Financial Impact

$1.71M in insider selling by C-suite executives, representing 0.021% of Nuvalent's $8.1B market cap

insider sentimentshareholder confidencepotential dilution risk

Risk Factors

  • Insider selling may precede negative news such as clinical trial setbacks or funding challenges
  • Perception of weakening leadership confidence could pressure stock despite small absolute size of sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1775075501840
11 reports for NUVL
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+1▲ +2.73%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
Type Now
Jun 9, 2026
today
8-K
BULLISH ★ 8/10
$122.90 awaiting T+20awaiting T+20$123.25 (+0.29%)
May 7, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$102.40 $90.18▼ −11.93%▼ −15.07%$123.25 (+20.36%)
Apr 29, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $107.38▲ +8.36%▲ +2.90%$123.25 (+24.37%)
Apr 7, 2026
9w ago
8-K
BULLISH ★ 7/10
$102.25 $102.62▲ +0.36%▼ −9.42%$123.25 (+20.54%)
Apr 6, 2026
9w ago
Insider Cluster
BEARISH ★ 6/10
$103.71 $102.62▲ +1.05%▲ +10.03%$123.25 (−18.84%)
Mar 30, 2026
10w ago
Insider Cluster
BEARISH ★ 7/10
$96.72 $101.94▼ −5.40%▲ +7.20%$123.25 (−27.43%)
Mar 26, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$98.06 $104.50▲ +6.57%▼ −4.10%$123.25 (+25.69%)
Mar 25, 2026
11w ago
Insider Cluster
BEARISH ★ 7/10
$98.00 $108.02▼ −10.22%▼ −2.36%$123.25 (−25.77%)
Mar 25, 2026
11w ago
Insider Cluster
BEARISH ★ 6/10
$98.00 $100.49▼ −2.54%▲ +5.32%$123.25 (−25.77%)
Mar 6, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$99.41 $103.71▲ +4.33%▲ +6.37%$123.25 (+23.98%)
Showing 10 of 11

US Market Status

Market Closed — Opens Thu (11h 15m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access